LinkedIn

 آمار

تعداد نشریات21
تعداد شماره‌ها1,304
تعداد مقالات11,933
تعداد مشاهده مقاله83,483,233
تعداد دریافت فایل اصل مقاله122,196,914
Danesh Pajooh, Fatemeh, Oryan, Shahrbanoo, Mortazavi, Pejman. (1405). Effect of Yttrium Oxide Nanoparticles on Liver Fibrosis Induced by Carbon Tetrachloride in Male Rats. سامانه مدیریت نشریات علمی, (), -. doi: 10.30476/ijms.2026.109288.4451
Fatemeh Danesh Pajooh; Shahrbanoo Oryan; Pejman Mortazavi. "Effect of Yttrium Oxide Nanoparticles on Liver Fibrosis Induced by Carbon Tetrachloride in Male Rats". سامانه مدیریت نشریات علمی, , , 1405, -. doi: 10.30476/ijms.2026.109288.4451
Danesh Pajooh, Fatemeh, Oryan, Shahrbanoo, Mortazavi, Pejman. (1405). 'Effect of Yttrium Oxide Nanoparticles on Liver Fibrosis Induced by Carbon Tetrachloride in Male Rats', سامانه مدیریت نشریات علمی, (), pp. -. doi: 10.30476/ijms.2026.109288.4451
Danesh Pajooh, Fatemeh, Oryan, Shahrbanoo, Mortazavi, Pejman. Effect of Yttrium Oxide Nanoparticles on Liver Fibrosis Induced by Carbon Tetrachloride in Male Rats. سامانه مدیریت نشریات علمی, 1405; (): -. doi: 10.30476/ijms.2026.109288.4451

Effect of Yttrium Oxide Nanoparticles on Liver Fibrosis Induced by Carbon Tetrachloride in Male Rats

Iranian Journal of Medical Sciences
مقالات آماده انتشار، اصلاح شده برای چاپ، انتشار آنلاین از تاریخ 07 مهر 1405    اصل مقاله (2.64 M)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2026.109288.4451
نویسندگان
Fatemeh Danesh Pajooh1؛ Shahrbanoo Oryan* 1، 2؛ Pejman Mortazavi3
1Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
2Department of Animal Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran
3Department of Pathology, School of Specialized Veterinary Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran
چکیده
Background: Yttrium oxide nanoparticles (Y2O3 NPs) are known as free radical absorbers. This study investigated the effects of Y2O3 NPs on antioxidant activities, liver enzymes, expression of alpha-smooth muscle actin (α-SMA) and transforming growth factor beta (TGF-β) genes, and histopathology in rat liver fibrosis.
Methods: In this experimental study conducted in 2019 at Islamic Azad University, Qom, Iran, male Wistar rats (200–220 g) were assigned to seven groups (n=8): Control, Vehicle, carbon tetrachloride (CCl4), Y2O3 45 mg/Kg, Y2O3 60 mg/Kg, CCl4+Y2O3 45 mg/Kg, and CCl4+Y2O3 60 mg/Kg. Liver fibrosis was induced by CCl4. Y2O3 NPs were administered intraperitoneally for 4 weeks. Blood and liver samples were collected for analyses. Statistical analysis was performed using SPSS (version 21) by one-way ANOVA and Tukey post hoc test. P<0.05 was considered significant.
Results: The findings indicated catalas (3.00±0.21 vs. 21.46±0.70, 8.96±20 U/min/mg, P<0.001), superoxide dismutase (3.13±0.21 vs. 44.36±1.99, 37.59±0.77 U/mg, P<0.001), glutathione peroxidase (135.25±4.02 vs. 492.00±27.87, 322.75±8.75, U/mg, P<0.001) activities increased, while malondialdehyde (1.29±0.86 vs. 0.32±0.03 , 0.49±0.06 nmol/mL, P<0.001), aspartate aminotransferase (286.33±2.89 vs. 154.66±9.00, 178.00±7.35 U/L, P<0.001), alkaline phosphatase (645.00±16.62 vs. 497.66±9.87, 321.75±20.03 U/L, P<0.001), gamma-glutamyl transferase (619.00±23.45 vs. 349.66±29.95, 299.25±2541 U/L, P<0.001) levels decreased. TGF-β and α-SMA expression decreased in terated groups (6.40±0.23 to 4.19±0.55, P=0.012, 2.70±0.46 P=0.009, 13.77 ±0.44 to 7.94±0.54 P=0.002, 4.87±0.35 P=0.033). Histology evaluatuons confirmed reduced inflammation, steatosis, and collagen deposition in Y2O3-treated fibrotic rats.
Conclusion: Y2O3 NPs can alleviate liver fibrosis in experiment.

تازه های تحقیق

Fatemeh Danesh Pajooh (Google Scholar) 
Shahrbanoo Oryan (Google Scholar) 

کلیدواژه‌ها
Yttrium oxide nanoparticles؛ Liver fibrosis؛ Carbon tetrachloride؛ Transforming growth factor beta؛ Alpha-smooth muscle actin؛ Wistar rats
مراجع
  1. Kalra A, Yetiskul E, Wehrle CJ, Tuma F. Physiology, liver. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2026 Feb 18]. Available from: https://www.statpearls.com/articlelibrary/viewarticle/36037
  2. Ehrlich A, Duche D, Ouedraogo G, Nahmias Y. Challenges and Opportunities in the Design of Liver-on-Chip Microdevices. Annu Rev Biomed Eng. 2019;21:219-39. doi: 10.1146/annurev-bioeng-060418-052305. PubMed PMID: 31167098; PubMed Central PMCID: PMC7004816.
  3. Acharya P, Chouhan K, Weiskirchen S, Weiskirchen R. Cellular Mechanisms of Liver Fibrosis. Front Pharmacol. 2021;12:671640. doi: 10.3389/fphar.2021.671640. PubMed PMID: 34025430; PubMed Central PMCID: PMC8134740.
  4. Nan Y, Su H, Lian X, Wu J, Liu S, Chen P, et al. Pathogenesis of Liver Fibrosis and Its TCM Therapeutic Perspectives. Evid Based Complement Alternat Med. 2022;2022:5325431. doi: 10.1155/2022/5325431. PubMed PMID: 35529927; PubMed Central PMCID: PMC9071861.
  5. Dhar D, Baglieri J, Kisseleva T, Brenner DA. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med (Maywood). 2020;245:96-108. doi: 10.1177/1535370219898141. PubMed PMID: 31924111; PubMed Central PMCID: PMC7016420.
  6. Yilma M, Saxena V, Mehta N. Models to Predict Development or Recurence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Hepatic Fibrosis. Curr Gastroenterol Rep. 2022;24:1-9. doi: 10.1007/s11894-022-00835-8. PubMed PMID: 35142988; PubMed Central PMCID: PMC8891098.
  7. Li X, Zhang Q, Wang Z, Zhuang Q, Zhao M. Immune and Metabolic Alterations in Liver Fibrosis: A Disruption of Oxygen Homeostasis? Front Mol Biosci. 2021;8:802251. doi: 10.3389/fmolb.2021.802251. PubMed PMID: 35187072; PubMed Central PMCID: PMC8850363.
  8. Frangogiannis N. Transforming growth factor-beta in tissue fibrosis. J Exp Med. 2020;217:e20190103. doi: 10.1084/jem.20190103. PubMed PMID: 32997468; PubMed Central PMCID: PMC7062524.
  9. Gupta P, Sata TN, Yadav AK, Mishra A, Vats N, Hossain MM, et al. TGF-beta induces liver fibrosis via miRNA-181a-mediated down regulation of augmenter of liver regeneration in hepatic stellate cells. PLoS One. 2019;14:e0214534. doi: 10.1371/journal.pone.0214534. PubMed PMID: 31166951; PubMed Central PMCID: PMC6550375.
  10. Komolkriengkrai M, Nopparat J, Vongvatcharanon U, Anupunpisit V, Khimmaktong W. Effect of glabridin on collagen deposition in liver and amelioration of hepatocyte destruction in diabetes rats. Exp Ther Med. 2019;18:1164-74. doi: 10.3892/etm.2019.7664. PubMed PMID: 31316610; PubMed Central PMCID: PMC6601403.
  11. Tian F, Liu Y, Gao J, Yang N, Shang X, Lv J, et al. Study on the association between TGF-beta1 and liver fibrosis in patients with hepatic cystic echinococcosis. Exp Ther Med. 2020;19:1275-80. doi: 10.3892/etm.2019.8355. PubMed PMID: 32010299; PubMed Central PMCID: PMC6966196.
  12. Gu L, Zhang F, Wu J, Zhuge Y. Nanotechnology in Drug Delivery for Liver Fibrosis. Front Mol Biosci. 2021;8:804396. doi: 10.3389/fmolb.2021.804396. PubMed PMID: 35087870; PubMed Central PMCID: PMC8787125.
  13. Yadav PK, Saklani R, Tiwari AK, Verma S, Rana R, Chauhan D, et al. Enhanced apoptosis and mitochondrial cell death by paclitaxel-loaded TPP-TPGS(1000)-functionalized nanoemulsion. Nanomedicine (Lond). 2023;18:343-66. doi: 10.2217/nnm-2022-0268. PubMed PMID: 37140535.
  14. Su S, P MK. Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems. Pharmaceutics. 2020;12. doi: 10.3390/pharmaceutics12090837. PubMed PMID: 32882875; PubMed Central PMCID: PMC7559885.
  15. Zhang P, Xia J, Luo S. Generation of Well-Defined Micro/Nanoparticles via Advanced Manufacturing Techniques for Therapeutic Delivery. Materials (Basel). 2018;11. doi: 10.3390/ma11040623. PubMed PMID: 29670013; PubMed Central PMCID: PMC5951507.
  16. Huang C, Chen X, Xue Z, Wang T. Effect of structure: A new insight into nanoparticle assemblies from inanimate to animate. Sci Adv. 2020;6:1321. doi: 10.1126/sciadv.aba1321. PubMed PMID: 32426506; PubMed Central PMCID: PMC7220353.
  17. Maslanka Figueroa S, Fleischmann D, Goepferich A. Biomedical nanoparticle design: What we can learn from viruses. J Control Release. 2021;329:552-69. doi: 10.1016/j.jconrel.2020.09.045. PubMed PMID: 33007365; PubMed Central PMCID: PMC7525328.
  18. Fish MB, Banka AL, Braunreuther M, Fromen CA, Kelley WJ, Lee J, et al. Deformable microparticles for shuttling nanoparticles to the vascular wall. Sci Adv. 2021;7. doi: 10.1126/sciadv.abe0143. PubMed PMID: 33883129; PubMed Central PMCID: PMC8059934.
  19. de la Torre P, Perez-Lorenzo MJ, Alcazar-Garrido A, Flores AI. Cell-Based Nanoparticles Delivery Systems for Targeted Cancer Therapy: Lessons from Anti-Angiogenesis Treatments. Molecules. 2020;25. doi: 10.3390/molecules25030715. PubMed PMID: 32046010; PubMed Central PMCID: PMC7038177.
  20. Gomes HIO, Martins CSM, Prior JAV. Silver Nanoparticles as Carriers of Anticancer Drugs for Efficient Target Treatment of Cancer Cells. Nanomaterials (Basel). 2021;11. doi: 10.3390/nano11040964. PubMed PMID: 33918740; PubMed Central PMCID: PMC8069134.
  21. Rajakumar G, Mao L, Bao T, Wen W, Wang S, Gomathi T, et al. Yttrium oxide nanoparticle synthesis: an overview of methods of preparation and biomedical applications. Appl Sci (Basel). 2021;11:2172. doi: 10.3390/app11052172.
  22. Navaei-Nigjeh M, Daniali M, Rahimifard M, Khaksar MR. Multi-organ Toxicity Attenuation by Cerium Oxide and Yttrium Oxide Nanoparticles: Comparing the Beneficial Effects on Tissues Oxidative Damage Induced by Sub-acute Exposure to Diazinon. Pharm Nanotechnol. 2020;8:225-38. doi: 10.2174/2211738508666200808135226. PubMed PMID: 32767961.
  23. Song X, Shang P, Sun Z, Lu M, You G, Yan S, et al. Therapeutic effect of yttrium oxide nanoparticles for the treatment of fulminant hepatic failure. Nanomedicine (Lond). 2019;14:2519-33. doi: 10.2217/nnm-2019-0154. PubMed PMID: 31317822.
  24. Akhtar MJ, Ahamed M, Alrokayan SA, Ramamoorthy MM, Alaizeri ZM. High Surface Reactivity and Biocompatibility of Y(2)O(3) NPs in Human MCF-7 Epithelial and HT-1080 FibroBlast Cells. Molecules. 2020;25. doi: 10.3390/molecules25051137. PubMed PMID: 32138335; PubMed Central PMCID: PMC7179248.
  25. Charles River Laboratories. Guide for the care and use of laboratory animals. Westborough: Charles River Laboratories; 2018.
  26. Kassem S, Arafa MM, Yehya MM, Soliman MAM. In vivo study of dose-dependent antioxidant efficacy of functionalized core-shell yttrium oxide nanoparticles. Naunyn Schmiedebergs Arch Pharmacol. 2022;395:593-606. doi: 10.1007/s00210-022-02219-1. PubMed PMID: 35201389; PubMed Central PMCID: PMC8989852.
  27. Tang KS. Antioxidant and Anti-inflammatory Properties of Yttrium Oxide Nanoparticles: New Insights into Alleviating Diabetes. Curr Diabetes Rev. 2021;17:496-502. doi: 10.2174/1573399816999201012201111. PubMed PMID: 33045978.
  28. Bancroft JD, Gamble M. Theory and practice of histological techniques. 8th ed. Amsterdam: Elsevier; 2019.
  29. Akanbi TO, Ojo S, Adedayo BM, Olayanju O, Akinpelu O. Antibacterial properties of yttrium oxide nanoparticles against multi-drug resistant bacteria. J Nanobiotechnology. 2021;19:123.
  30. Mohamed HRH, Farouk AH, Elbasiouni SH, Nasif KA, Safwat G. Yttrium oxide nanoparticles ameliorates calcium hydroxide and calcium titanate nanoparticles induced genomic DNA and mitochondrial damage, ROS generation and inflammation. Sci Rep. 2024;14:13015. doi: 10.1038/s41598-024-62877-4. PubMed PMID: 38844752; PubMed Central PMCID: PMC11156978.
  31. Wali AF, Ali S, Rashid S, Alsaffar RM, Arafah A, Qamar W, et al. Attenuation of oxidative damage-associated hepatotoxicity by piperine in CCl4-induced liver fibrosis. J King Saud Univ Sci. 2021;33:101629. doi: 10.1016/j.jksus.2021.101629. doi: 10.1016/j.jksus.2021.101629.
  32. Izzularab BM, Megeed M, Yehia M. Propolis nanoparticles modulate the inflammatory and apoptotic pathways in carbon tetrachloride-induced liver fibrosis and nephropathy in rats. Environ Toxicol. 2021;36:55-66. doi: 10.1002/tox.23010. PubMed PMID: 32840962.
  33. Dutta S, Chakraborty AK, Dey P, Kar P, Guha P, Sen S, et al. Amelioration of CCl4 induced liver injury in swiss albino mice by antioxidant rich leaf extract of Croton bonplandianus Baill. PLoS One. 2018;13:e0196411. doi: 10.1371/journal.pone.0196411. PubMed PMID: 29709010; PubMed Central PMCID: PMC5927454.
  34. Abbasi E, Vafaei SA, Naseri N, Darini A, Azandaryani MT, Ara FK, et al. Protective effects of cerium oxide nanoparticles in non-alcoholic fatty liver disease (NAFLD) and carbon tetrachloride-induced liver damage in rats: Study on intestine and liver. Metabol Open. 2021;12:100151. doi: 10.1016/j.metop.2021.100151. PubMed PMID: 34870139; PubMed Central PMCID: PMC8626579.
  35. Abdorrashidi M, Peypar MH, Tohidinia A, Zali F, Eisazadeh S, Abyazi MA, et al. Efforts Focused on Fatty Liver over Two Years (2023-2025): A Thematic Literature Review. Iran J Pathol. 2025;20:355-66. doi: 10.30699/ijp.2025.2047720.3391. PubMed PMID: 41099052; PubMed Central PMCID: PMC12520595.
  36. Ogaly HA, Aldulmani SAA, Al-Zahrani FAM, Abd-Elsalam RM. D-Carvone Attenuates CCl(4)-Induced Liver Fibrosis in Rats by Inhibiting Oxidative Stress and TGF-ss 1/SMAD3 Signaling Pathway. Biology (Basel). 2022;11. doi: 10.3390/biology11050739. PubMed PMID: 35625467; PubMed Central PMCID: PMC9138456.
  37. Wu S, Liu L, Yang S, Kuang G, Yin X, Wang Y, et al. Paeonol alleviates CCl(4)-induced liver fibrosis through suppression of hepatic stellate cells activation via inhibiting the TGF-beta/Smad3 signaling. Immunopharmacol Immunotoxicol. 2019;41:438-45. doi: 10.1080/08923973.2019.1613427. PubMed PMID: 31119954.
  38. Ribera J, Rodriguez-Vita J, Cordoba B, Portoles I, Casals G, Casals E, et al. Functionalized cerium oxide nanoparticles mitigate the oxidative stress and pro-inflammatory activity associated to the portal vein endothelium of cirrhotic rats. PLoS One. 2019;14:e0218716. doi: 10.1371/journal.pone.0218716. PubMed PMID: 31233564; PubMed Central PMCID: PMC6590813.v
  39. Feng S, Tong H, Gao JH, Tang SH, Yang WJ, Wang GM, et al. Anti-inflammation treatment for protection of hepatocytes and amelioration of hepatic fibrosis in rats. Exp Ther Med. 2021;22:1213. doi: 10.3892/etm.2021.10647. PubMed PMID: 34584558; PubMed Central PMCID: PMC8422404.
  40. Tanwar S, Rhodes F, Srivastava A, Trembling PM, Rosenberg WM. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C. World J Gastroenterol. 2020;26:109-33. doi: 10.3748/wjg.v26.i2.109. PubMed PMID: 31969775; PubMed Central PMCID: PMC6962431.
  41. Chen L, Zhang Q, Yu C, Wang F, Kong X. Functional roles of CCL5/RANTES in liver disease. Liver Res. 2020;4:28-34. doi: 10.1016/j.livres.2020.01.002. doi: 10.1016/j.livres.2020.01.002.
  42. Panyala A, Chinde S, Kumari SI, Rahman MF, Mahboob M, Kumar JM, et al. Comparative study of toxicological assessment of yttrium oxide nano- and microparticles in Wistar rats after 28 days of repeated oral administration. Mutagenesis. 2019;34:181-201. doi: 10.1093/mutage/gey044. PubMed PMID: 30753658.
آمار
تعداد مشاهده مقاله: 9
تعداد دریافت فایل اصل مقاله: 1


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب